Cargando…

Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus

Purpose The objective of this study was to explore the optimal cholesterol-lowering therapy for diabetic patients categorized as having a very high risk for future atherosclerotic cardiovascular disease (ASCVD) events. The primary medications under investigation were statins, ezetimibe, and proprote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saag, Jordan L, Gross, Dennis, Stirt, Daniel, Espina Rey, Andrea, Gros, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365890/ https://www.ncbi.nlm.nih.gov/pubmed/37492827 http://dx.doi.org/10.7759/cureus.40905

Ejemplares similares

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Small Dense Low-Density Lipoprotein Level in Newly Diagnosed Type 2 Diabetes Mellitus Patients With Normal Low-Density Lipoprotein
por: Juhi, Ayesha, et al.
Publicado: (2023)

Bempedoic Acid’s Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review
por: Goit, Raman, et al.
Publicado: (2022)

Are We Nuts Over Coconuts? Studying the Effects of Coconut Oil on Low-Density Lipoprotein and Cardiovascular Diseases: A Systematic Review
por: Sekhar, Supriya, et al.
Publicado: (2022)

The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study
por: Chang, Chin-Huan, et al.
Publicado: (2023)

Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE)
por: Mehta, Ashwani, et al.
Publicado: (2022)

The Relationship Between Iron Status and Atherosclerotic Cardiovascular Disease Risk in Non-anemic Patients Without a History of Cardiovascular Diseases: A Cross-Sectional Study
por: Skrzypczak, Tomasz, et al.
Publicado: (2022)

Association Between Self-Rated Health and Medical Care Disruption Due to COVID-19 Among Individuals With Atherosclerotic Cardiovascular Disease
por: Hussain, Akbar, et al.
Publicado: (2023)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease
por: Gao, Shen, et al.
Publicado: (2017)

Utility of Coronary Artery Calcium Scores in Predicting Risk of Subclinical Cardiovascular Atherosclerotic Disease: An Analysis of Limitations to its Adoption With Policy Recommendations
por: Ali, Muhammad M, et al.
Publicado: (2021)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

The triglycerides-glucose index and the triglycerides to high-density lipoprotein cholesterol ratio are both effective predictors of in-hospital death in non-diabetic patients with AMI
por: Guo, Jiaqi, et al.
Publicado: (2022)

Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction
por: Park, Jin Sup, et al.
Publicado: (2019)

Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins
por: Lawler, Patrick R., et al.
Publicado: (2017)

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
por: Robinson, Jennifer G., et al.
Publicado: (2018)

A Rare Double Heterozygous Mutation in Low-Density Lipoprotein Receptor and Apolipoprotein B-100 Genes in a Severely Affected Familial Hypercholesterolaemia Patient
por: Juhász, Lilla, et al.
Publicado: (2020)

Non-Atherosclerotic Myocardial Infarction With a Presentation of Wellens Syndrome
por: Jamshaid, Muhammad B, et al.
Publicado: (2020)

Comparison of Atherosclerotic Plaque Compositions in Diabetic and Non-diabetic Patients
por: Çakır, Mustafa Ozan, et al.
Publicado: (2023)

High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease
por: Ito, Fumiaki, et al.
Publicado: (2020)

Editorial: Transitional Care Clinics to Reduce 30-day Readmissions in Heart Failure Patients
por: Smith, Katherine, et al.
Publicado: (2018)

The Role of the Automated Implantable Cardioverter Defibrillator (AICD) for Secondary Prevention in the COVID-19 Era
por: Doodnauth, Andrew V, et al.
Publicado: (2021)

Association of circulating microRNA-122 with presence and severity of atherosclerotic lesions
por: Wang, Yu-Long, et al.
Publicado: (2018)

Nicorandil, Novel Potassium Adenosine Triphosphate Channel (K+ ATP) Opener in Ischemia With Non-Obstructive Coronary Arteries (INOCA) and Atherosclerotic Cardiovascular Disease (ASCVD): Delphi Consensus Statement
por: Chakraborty, Rabin
Publicado: (2023)

Musculoskeletal Conditions and Secondary Cardiovascular Morbidity Increase Veterans’ Rehabilitation and Orthopaedic Service Utilization
por: Rivera, Jessica C, et al.
Publicado: (2022)

Is the Renal Resistive Index a Marker for Revascularization in Atherosclerotic Renal Artery Stenosis?
por: Vemireddy, Lalitha Padmanabha, et al.
Publicado: (2021)

Exploring the Subclinical Atherosclerotic Load in Patients With Rheumatoid Arthritis: A Cross-Sectional Study
por: Arora, Arpit, et al.
Publicado: (2022)

“Acing” the Hidden Spade: Review of Diagnosis, Follow-up, Prognosis, and Various Associations of Apical Variant Hypertrophic Cardiomyopathy
por: Patel, Hiren, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review
por: Wahinya, Maureen, et al.
Publicado: (2023)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
por: Packard, Chris, et al.
Publicado: (2021)

High-Density Lipoprotein Nanoparticle Imaging in Atherosclerotic Vascular Disease
por: Leeper, Nicholas J., et al.
Publicado: (2017)

Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases
por: Ivanova, Ekaterina A., et al.
Publicado: (2017)

Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients
por: Peela, Jagannadha R, et al.
Publicado: (2018)

A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease
por: Igweonu-Nwakile, Emmanuelar O, et al.
Publicado: (2022)

Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
por: Choi, Su-Yeon, et al.
Publicado: (2020)

Prevalence of Cardiovascular Risk Factors Among Patients With Diabetes Mellitus Type 2 at King Fahad University Hospital, Saudi Arabia
por: Jatoi, Noor-Ahmed, et al.
Publicado: (2022)

Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study
por: Ersbøll, Annette Kjær, et al.
Publicado: (2023)

Erosion of Cardiovascular Implantable Device: Conservative Therapy or Extraction?
por: Tabbah, Randa N, et al.
Publicado: (2020)

Gender-specific secondary prevention? Differential psychosocial risk factors for major cardiovascular events
por: Kure, Christina E, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3rtpfqfkmjgskmi3qvilpsuavt